Noninvasive Detection of Esophageal Cancer by the Combination of mSEPT9 and SNCG
Genetic Testing and Molecular Biomarkers · 01.01.2022 · 26 (1) · 8-16
DOI: 10.1089/gtmb.2021.0089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetic Testing and Molecular Biomarkers, erschienen am 01.01.2022. Verfasst von Lei Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. China. Hauptthemen laut MEDLINE: Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Esophageal cancer (EC) is the second most common malignant tumor of the digestive system. There is currently no effective noninvasive method for early detection of EC.
Methods
We performed a prospective cohort study involving 188 EC patients, 125 patients with benign esophageal diseases, and 270 normal subjects to examine the performance of methylated SEPT9 (mSEPT9) and synuclein gamma (SNCG) individually and in combination.
Results
The sensitivity of mSEPT9 and SNCG for EC was 43.1% (AUC = 0.69) at 95.6% specificity and 41.8% (AUC = 0.79) at 92.6% specificity, respectively. The combined detection increased the sensitivity to 71.8% at 90.3% specificity. The combined detection sensitivity for stage I-IV EC was 66.7%, 58.3%, 75.0%, and 88.2%, respectively. No significant difference in combined sensitivity was found among patients with EC of the upper, middle, and lower esophagus, and no significant difference in sensitivity was found between adenocarcinoma and squamous carcinoma. The sensitivity of highly differentiated EC was found to be higher than that of moderately and poorly differentiated EC with SNCG and combined detection. The sensitivity of SNCG in female patients was significantly higher than that in male patients, leading to the same trend in combined detection. Patients aged 40-49 years showed higher combined sensitivity. The sensitivity of SNCG was much higher than that of existing protein markers for digestive cancers. Furthermore, mSEPT9 was capable of predicting the long-term survival of EC patients with a hazard ratio of 2.65.
Conclusion
The combined sensitivity of mSEPT7 and SNGG provided significant improvement over any single biomarker for the early detection of EC. mSEPT7 may be useful as a prognostic marker for long-term survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. China.
ORCID-Profile: Lei Zhang
Zitieren
APA
Zhang, L., Yang, X., Tian, Y., Yu, Q., Zhou, D., Wu, Z., & Zhao, X. (2022). Noninvasive Detection of Esophageal Cancer by the Combination of mSEPT9 and SNCG. Genetic Testing and Molecular Biomarkers, 26(1), 8-16. https://doi.org/10.1089/gtmb.2021.0089
Vancouver
Zhang L, Yang X, Tian Y, Yu Q, Zhou D, Wu Z, et al. Noninvasive Detection of Esophageal Cancer by the Combination of mSEPT9 and SNCG. Genetic Testing and Molecular Biomarkers. 2022;26(1):8-16. doi:10.1089/gtmb.2021.0089
BibTeX
@article{Zhang2022,
author = {Zhang, Lei and Yang, Xueying and Tian, Ye and Yu, Qian and Zhou, Di and Wu, Zhuo and Zhao, Xitong},
title = {Noninvasive Detection of Esophageal Cancer by the Combination of mSEPT9 and SNCG},
journal = {Genetic Testing and Molecular Biomarkers},
year = {2022},
volume = {26},
number = {1},
pages = {8--16},
doi = {10.1089/gtmb.2021.0089}
}
EUVIMED